The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prevalence of nonmetastatic (M0) prostate cancer (PC) patients on continuous androgen deprivation therapy (ADT) in the United States.
Karynsa Cetin
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Shuling Li
Research Funding - Amgen
Anne Hudson Blaes
Research Funding - Amgen
Scott Stryker
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Alexander Liede
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Thomas J. Arneson
Research Funding - Amgen